Scinai Immunotherapeutics Reports Strong Growth, Advances NanoAb Pipeline
September 2, 2025 — Scinai Immunotherapeutics reports 172% revenue growth, narrowed losses, and advances anti-IL-17 NanoAb program. Read about their CDMO success and clinical pipeline progress.